查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1602657

AlphaGlucosidase抑制剂市场：按药物类别、分销管道、最终用户划分 - 全球预测 2025-2030

Alpha Glucosidase Inhibitors Market by Drug class (Acarbose (Precose), Miglitol (Glyset), Voglibose), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年阿尔法葡萄Glucosidase抑制剂市值为61,676万美元，预计2024年将达到7,0376万美元，复合年增长率为14.50%，预计2030年将达到159,149万美元。

α-葡萄Glucosidase抑制剂（AGI）是一种口服抗糖尿病药物，可减缓肠道中碳水化合物的吸收，从而减缓 2 型糖尿病患者餐后血糖值的上升。全球糖尿病盛行率的上升凸显了对 AGI 的需求，这刺激了对补充生活方式介入和其他糖尿病治疗的有效管理策略的需求。 AGI 主要用于治疗第 2 型糖尿病，但正在进行的研究也在调查其在其他代谢疾病中的潜在用途。最终用途范围主要包括医院、诊所、零售药房以及为全球患者提供便利的线上药局。这个市场主要是由糖尿病患者数量的增加、药物配方的进步以及糖尿病管理意识的提高所推动的。新兴市场存在机会，医疗基础设施改善，抗糖尿病药物的取得也有所改善。然而，增长受到胃肠道疾病等副作用以及提供更全面血糖控制的新药物类别的出现的限制。低收入地区也面临价格敏感性和药品审批严格监管要求的挑战。创新包括优化 AGI 的药物动力学以最大限度地减少副作用和提高患者的依从性，以及开发利用 AGI 和其他抗糖尿病药物的互补作用的联合治疗可以成为焦点。此外，透过探索整合 AGI 的营养和生活方式干预措施，可能会出现市场扩张的新途径。市场的本质是动态的，竞争格局的特征是大量的研发活动，因为公司努力透过产品差异化和有效性来获得优势。为了抓住新的商机，企业应该透过研发、监管合规以及与研究机构和医疗保健提供者的策略联盟来投资扩大通用人工智慧的应用范围。

主要市场统计
基准年[2023] 61676万美元
预测年份 [2024] 70376万美元
预测年份 [2030] 15.9149亿美元
复合年增长率（%） 14.50%

市场动态：揭示快速发展的阿尔法Glucosidase抑制剂市场的关键市场洞察

供需的动态交互作用正在改变α-Glucosidase抑制剂市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 2 型糖尿病的流行和改进治疗的需要
    • 鼓励糖尿病管理的政府措施和措施
    • α-Glucosidase酶抑制剂联合治疗日益受到关注
  • 市场限制因素
    • 原料药核准和给药方案的困难
  • 市场机会
    • 持续研发活动以创造新的α-Glucosidase抑制剂
    • 提高 α-Glucosidase抑制剂疗效的个人化医疗方法
  • 市场问题
    • 对消化器官系统道副作用和药物交互作用的担忧

波特的五力：驾驭阿尔法葡萄Glucosidase抑制剂市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解α葡萄Glucosidase抑制剂市场的外部影响

外部宏观环境因素在塑造α-Glucosidase抑制剂市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解α-Glucosidase抑制剂市场的竞争格局

对阿尔法葡萄Glucosidase抑制剂市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：α 葡萄Glucosidase抑制剂市场供应商的绩效评估

FPNV定位矩阵是评估α-Glucosidase抑制剂市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製阿尔法葡萄Glucosidase抑制剂市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对阿尔法Glucosidase抑制剂市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争格局中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 2 型糖尿病的盛行率和改善护理的需要
      • 政府促进糖尿病管理的措施和措施
      • 与α-Glucosidase抑制剂的联合治疗越来越受到关注
    • 抑制因素
      • API核准和给药方案的困难
    • 机会
      • 持续研发活动以发现新的α-Glucosidase抑制剂
      • 提高 α-Glucosidase抑制剂疗效的个人化医疗方法
    • 任务
      • 对胃肠道副作用和药物交互作用的担忧
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章 α 葡萄Glucosidase抑制剂市场：依药物类别

  • 介绍
  • Acarbose（预防）
  • 米格列醇（Griset）
  • 伏格列波糖

第七章α葡萄Glucosidase抑制剂市场：按分销管道

  • 介绍
  • 医院药房
  • 网路药房
  • 零售药房

第 8 章 α 葡萄Glucosidase抑制剂市场：依最终用户分类

  • 介绍
  • 居家医疗
  • 医院/诊所
  • 糖尿病专科中心

第九章北美和南美α葡萄Glucosidase抑制剂市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区α-Glucosidase抑制剂市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第11章α-欧洲、中东和非洲的Glucosidase抑制剂市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Alkem Laboratories Ltd.
  • Avecia Healthcare
  • Bal Pharma Ltd.
  • Bayer AG
  • Biocon
  • BioVision Inc. by Abcam US Group Holdings Inc.
  • Cipla Ltd.
  • Elder Pharmaceuticals Ltd.
  • Empros Pharma AB
  • Glenmark Pharmaceuticals Ltd.
  • Lunan Pharmaceuticals Group
  • Manus Aktteva Biopharma LLP
  • Merck KGaA
  • Micro Labs Ltd.
  • Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
  • Novo Nordisk A/S
  • Samex Overseas
  • Sanofi SA
  • Shenzhen Haorui Pharmatech Co., Ltd.
  • Straight Healthcare
  • Strides Arcolab Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Wockhardt Ltd.
Product Code: MRR-456C7E866918

The Alpha Glucosidase Inhibitors Market was valued at USD 616.76 million in 2023, expected to reach USD 703.76 million in 2024, and is projected to grow at a CAGR of 14.50%, to USD 1,591.49 million by 2030.

Alpha Glucosidase Inhibitors (AGIs) are a class of oral antidiabetic medications that delay the absorption of carbohydrates in the intestine, thereby mitigating postprandial blood glucose spikes in Type 2 diabetes patients. Their necessity is underscored by the global rise in diabetes prevalence, fueling demand for effective management strategies that complement lifestyle interventions and other diabetic therapies. AGIs find applications primarily in managing Type 2 diabetes, but ongoing research is examining their potential use in other metabolic disorders. The end-use scope predominantly includes hospitals, clinics, and retail pharmacies, as well as online drug stores that facilitate easier access to patients globally. The market is primarily driven by the increasing number of diabetes patients, advances in drug formulations, and rising awareness about diabetes management. Opportunities arise in emerging markets with growing healthcare infrastructure and increasing accessibility to antidiabetic drugs. However, growth is limited by side effects such as gastrointestinal issues and the advent of newer drug classes that offer more comprehensive glycemic control. Price sensitivity in low-income regions and stringent regulatory requirements for drug approval also pose challenges. Innovations could focus on optimizing the pharmacokinetics of AGIs to minimize side effects and enhance patient adherence, as well as developing combination therapies that leverage the complementary benefits of AGIs with other antidiabetic drugs. Exploring nutritional and lifestyle interventions integrated with AGIs could also reveal new avenues for market expansion. The nature of the market is dynamic, with a competitive landscape characterized by significant research and development activities as companies strive to gain an edge through product differentiation and efficacy. To grasp emerging opportunities, businesses should invest in R&D, regulatory compliance, and broadening the scope of AGIs applications through strategic partnerships with research institutions and healthcare providers.

KEY MARKET STATISTICS
Base Year [2023] USD 616.76 million
Estimated Year [2024] USD 703.76 million
Forecast Year [2030] USD 1,591.49 million
CAGR (%) 14.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alpha Glucosidase Inhibitors Market

The Alpha Glucosidase Inhibitors Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of type 2 diabetes and need for improved care
    • Government initiatives and policies encouraging diabetes management
    • Increasing focus on combination therapies with alpha-glucosidase inhibitors
  • Market Restraints
    • Difficulties of API approval and dosing regimen
  • Market Opportunities
    • Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
    • Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
  • Market Challenges
    • Concerns associated with gastrointestinal side effects and drug interactions

Porter's Five Forces: A Strategic Tool for Navigating the Alpha Glucosidase Inhibitors Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alpha Glucosidase Inhibitors Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alpha Glucosidase Inhibitors Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alpha Glucosidase Inhibitors Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alpha Glucosidase Inhibitors Market

A detailed market share analysis in the Alpha Glucosidase Inhibitors Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alpha Glucosidase Inhibitors Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alpha Glucosidase Inhibitors Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alpha Glucosidase Inhibitors Market

A strategic analysis of the Alpha Glucosidase Inhibitors Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alpha Glucosidase Inhibitors Market, highlighting leading vendors and their innovative profiles. These include Alkem Laboratories Ltd., Avecia Healthcare, Bal Pharma Ltd., Bayer AG, Biocon, BioVision Inc. by Abcam US Group Holdings Inc., Cipla Ltd., Elder Pharmaceuticals Ltd., Empros Pharma AB, Glenmark Pharmaceuticals Ltd., Lunan Pharmaceuticals Group, Manus Aktteva Biopharma LLP, Merck KGaA, Micro Labs Ltd., Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd., Novo Nordisk A/S, Samex Overseas, Sanofi S.A., Shenzhen Haorui Pharmatech Co., Ltd., Straight Healthcare, Strides Arcolab Limited, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Torrent Pharmaceuticals Ltd., and Wockhardt Ltd..

Market Segmentation & Coverage

This research report categorizes the Alpha Glucosidase Inhibitors Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug class, market is studied across Acarbose (Precose), Miglitol (Glyset), and Voglibose.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End-Users, market is studied across Home Healthcare, Hospitals & Clinics, and Specialty Diabetes Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of type 2 diabetes and need for improved care
      • 5.1.1.2. Government initiatives and policies encouraging diabetes management
      • 5.1.1.3. Increasing focus on combination therapies with alpha-glucosidase inhibitors
    • 5.1.2. Restraints
      • 5.1.2.1. Difficulties of API approval and dosing regimen
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities for new alpha-glucosidase inhibitor discovery
      • 5.1.3.2. Personalized medicine approaches for improved alpha-glucosidase inhibitor efficacy
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with gastrointestinal side effects and drug interactions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alpha Glucosidase Inhibitors Market, by Drug class

  • 6.1. Introduction
  • 6.2. Acarbose (Precose)
  • 6.3. Miglitol (Glyset)
  • 6.4. Voglibose

7. Alpha Glucosidase Inhibitors Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Pharmacies
  • 7.4. Retail Pharmacies

8. Alpha Glucosidase Inhibitors Market, by End-Users

  • 8.1. Introduction
  • 8.2. Home Healthcare
  • 8.3. Hospitals & Clinics
  • 8.4. Specialty Diabetes Centers

9. Americas Alpha Glucosidase Inhibitors Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alpha Glucosidase Inhibitors Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alpha Glucosidase Inhibitors Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alkem Laboratories Ltd.
  • 2. Avecia Healthcare
  • 3. Bal Pharma Ltd.
  • 4. Bayer AG
  • 5. Biocon
  • 6. BioVision Inc. by Abcam US Group Holdings Inc.
  • 7. Cipla Ltd.
  • 8. Elder Pharmaceuticals Ltd.
  • 9. Empros Pharma AB
  • 10. Glenmark Pharmaceuticals Ltd.
  • 11. Lunan Pharmaceuticals Group
  • 12. Manus Aktteva Biopharma LLP
  • 13. Merck KGaA
  • 14. Micro Labs Ltd.
  • 15. Miglitol-Zhejiang Ausun Pharmaceutical Co., Ltd.
  • 16. Novo Nordisk A/S
  • 17. Samex Overseas
  • 18. Sanofi S.A.
  • 19. Shenzhen Haorui Pharmatech Co., Ltd.
  • 20. Straight Healthcare
  • 21. Strides Arcolab Limited
  • 22. Sun Pharmaceutical Industries Ltd.
  • 23. Takeda Pharmaceutical Co. Ltd.
  • 24. Torrent Pharmaceuticals Ltd.
  • 25. Wockhardt Ltd.

LIST OF FIGURES

  • FIGURE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET RESEARCH PROCESS
  • FIGURE 2. ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALPHA GLUCOSIDASE INHIBITORS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALPHA GLUCOSIDASE INHIBITORS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ACARBOSE (PRECOSE), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY MIGLITOL (GLYSET), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY VOGLIBOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY SPECIALTY DIABETES CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ALPHA GLUCOSIDASE INHIBITORS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 146. ALPHA GLUCOSIDASE INHIBITORS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 147. ALPHA GLUCOSIDASE INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2023